BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cathay Industrial Biotech Completes US$52 Million Series B Financing


12/4/2006 11:03:00 AM

SHANGHAI, China, Dec. 4 /Xinhua-PRNewswire/ -- Cathay Industrial Biotech Ltd. (CIB) today announced the closing of its US$52 million Series B financing. Together with the US$26 million Series A financing in May 2006, CIB has raised a total of US$78 million in 2006.

Series B Investors include Goldman Sachs, Gramineae Holdings Company Limited, GM Investment Company Limited, and New Horizon Evergreen Investment Co, Ltd. Series A investors collectively also participated in the Series B financing.

The funds raised in the financings will be partially used to improve Cathay's long chain dibasic acids (DC) production technology by replacing the starting raw material from the traditional alkane (petroleum product) to renewable bio-materials. This conversion will reduce Cathay's dependence on the petroleum product and allow Cathay's and Cathay's customer's products to carry the ''green and renewable'' label. Part of the funds raised in the financings will be used to start a new ''green energy'' and renewable bio- material program, which converts starch and fiber into a unique type of bio- fuel with better burn energy than ethanol.

''We are very pleased with the successful closing of our two financings in 2006. The involvement of these leading international investors provides Cathay access to the international capital markets to accommodate its fast growing capital needs,'' said Dr. Xiucai Liu, Cathay's founder, Chairman and CEO. ''From now on, we will accelerate our speed of growth. We have full confidence to become a world-class industrial biotech company."

About Cathay Industrial Biotech

Cathay Industrial Biotech (CIB) is a leading international industrial biotechnology company headquartered in Shanghai Pudong Zhangjiang High-Tech Zone. Cathay is currently the largest producer of bio-processed DC in the world. Through Cathay's biotech process, the DC products are tailored to many applications such as new types of high quality nylons, special fragrance, adhesives, superior anti-corrosive chemicals, and high-grade powder coating for cars. These products are widely used in automobiles, electronics, cosmetics, and many other industries.

For more information, please contact: Li Zhu, PhD. VP Research and CSO, Cathay Biotechnology Tel: +86-21-5080-1916 x230 Email: zhuli@cathaybiotech.com Web: http://www.cathaybiotech.com

Cathay Industrial Biotech Ltd. (CIB)

CONTACT: Li Zhu, PhD., VP Research and CSO of Cathay Biotechnology,+86-21-5080-1916 x230, or zhuli@cathaybiotech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES